SUMMARY:
- The debate around Biogen’s Alzheimer’s drug continues to rage.
- The clinical evidence supporting the approval of the drug is at best “weak.”
- How could the FDA approve a drug with such poor clinical data?
- How can Biogen’s employees continue to work for a company that is raping taxpayers for a drug that doesn’t work?